Adult and children seizure-count data under levetiracetam add-on treatment of focal seizures were described using a population concentration–effect model. |
Effects of brivaracetam in adults were scaled to children using an adult brivaracetam population concentration-effect model, a pediatric brivaracetam population pharmacokinetic model, and the estimated scaling from adults to children (≥4 years) for levetiracetam. |
Maximum response is predicted with brivaracetam 4 mg/kg/day dosing (capped at 200 mg/day, the maximum adult dose) in children aged ≥4 years. |
1 Introduction
2 Methods
2.1 Data
Study | Population trial type drug N active/placeboa
| Treatment regimen and entry criteria |
---|---|---|
N051 | Adult phase III levetiracetam 234/0 | 12 weeks baseline assessment, followed by two 16-week crossover periods (4 weeks transition and 12 weeks evaluation) with two of three possible treatments of placebo, and 1000 or 2000 mg/day levetiracetam as bid administration, and a 4-week withdrawal period. Subjects were required to have at least four POS per 4 weeks prior to treatment administration |
N052 | Adult phase III levetiracetam 80/40 | 4 weeks baseline assessment, 24 weeks of placebo, 2000 or 4000 mg/day levetiracetam as bid administration without uptitration. Subjects were required to have at least four seizures of any type in the 24 weeks prior to treatment administration |
N132 | Adult phase III levetiracetam 120/40 | 12 weeks baseline assessment, 4 weeks uptitration, 14 weeks of placebo, and 1000 or 3000 mg/day levetiracetam as bid administration, 8 weeks down-titration or conversion to open long-term follow-up study. Subjects were required to have at least two POS per 4 weeks prior to treatment administration |
N138 | Adult phase III levetiracetam 172/86 | 12 weeks baseline assessment, 4 weeks uptitration, 12 weeks of placebo, or 3000 mg/day levetiracetam as bid administration, followed by a monotherapy study in responding subjects (monotherapy not analyzed). Subjects were required to have at least two complex POS per 4 weeks prior to treatment administration |
N159 | Pediatric phase III levetiracetam 100/100 | 8 weeks baseline assessment, three 2-week fixed-dose titration intervals (20, 40, and 60 mg/kg/day levetiracetam, capped at 1000, 2000 and 3000 mg/day, respectively, as bid administration), followed by 8 weeks at the maximum tolerated dose, and a 6-week withdrawal period. Subjects were required to have at least four POS per 4 weeks prior to treatment administration |
N01252 | Adult phase III brivaracetam 300/100 | 8 weeks baseline assessment, 12 weeks of 20, 50, or 100 mg/day brivaracetam as bid administration. Subjects were required to have at least two POS per month prior to treatment administration |
N01253 | Adult phase III brivaracetam 300/100 | 8 weeks baseline assessment, 12 weeks of 5, 20, or 50 mg/day brivaracetam as bid administration. Subjects were required to have at least two POS per month prior to treatment administration |
N01358 | Adult phase III brivaracetam 480/240 | 8 weeks baseline assessment, 12 weeks of 100 or 200 mg/day brivaracetam as bid administration. Subjects were required to have at least two POS per month prior to treatment administration |
N01263 | Pediatric phase IIa brivaracetam 100/0 | 1-week baseline assessment, 3-week evaluation period with a weekly fixed three–step uptitration of 0.8, 1.6, and 3.2 mg/kg/day as bid administration of oral solution for subjects ≥8 years of age, and 1.0, 2.0, and 4.0 mg/kg/day as bid administration of oral solution for subjects <8 years of age. Subjects were required to have at least one seizure (any type) during the 3 weeks prior to treatment administration |
Levetiracetam | Brivaracetam | |||
---|---|---|---|---|
Adults | Children | Adults | Children | |
Categorical data [n (%)] | ||||
Total number of subjects | 883 | 211 | 1912 | 96 |
Sex | ||||
Female | 407 (46.1) | 102 (48.3) | 945 (49.4) | 49 (51.0) |
Male | 476 (53.9) | 109 (51.7) | 967 (50.6) | 47 (49.0) |
AED background | ||||
Carbamazepine | 610 (69.1) | 73 (34.6) | 764 (40.0) | 9 (9.4) |
Phenytoin | 192 (21.7) | 15 (7.1) | 205 (10.7) | 1 (1.0) |
Phenobarbital | 122 (13.8) | 11 (5.2) | 139 (7.3) | 16 (16.7) |
Inducer AEDs | 770 (87.2) | 92 (43.6) | 1000 (52.3) | 25 (26.0) |
Continuous data [median (minimum/maximum)] | ||||
Weight, kg | 73 (39/140) | 34 (12/87) | 71 (24/176) | 19 (3.9/75) |
Age, years | 37 (14/70) | 10 (3/17) | 37 (15/80) | 5 (0.2/15) |
Baseline seizure frequency, day−1
| 0.306 (0.073/24.3) | 0.750 (0.099/99.7) | 0.321 (0.029/32.8) | Not assessed |
2.2 Software
2.3 Development of Population Pharmacokinetic (PK) Model for Levetiracetam in Adults and Children
2.4 Existing Population Pharmacokinetic/Pharmacodynamic (PK/PD) Model for Brivaracetam
2.5 Adaptation of the Existing Brivaracetam PK/PD Model to Levetiracetam Study Data
2.6 Levetiracetam PK/PD Model Qualification: Predictive Checks
2.7 Brivaracetam Pediatric PK/PD Simulations
3 Results
3.1 Levetiracetam Population PK Model for Adults and Pediatric Patients ≥4 Years
Parameter | Estimate (95% CI) | SE (%CV) | IIV (%) | Shrinkage (%) |
---|---|---|---|---|
CL/F, L/h | 3.38 (3.22–3.54) | 2.4 | 23.5 | 18.7 |
V/F, L | 48.7 (46.0–51.5) | 2.9 | 22.9 | 52.7 |
K
a, 1/h | 2.98 (2.98–2.98) | 0.0 | 241.5 | 42.8 |
Allometric scaling factor CL/F | 0.521 (0.477–0.566) | 4.4 | ||
Allometric scaling factor V/F | 0.789 (0.675–0.904) | 7.4 | ||
IND change on CL/F, % | 28.1 (21.8–34.7) | 10.3 | ||
Proportional residual error; CV, % | 26.9 (25.5–28.2) | 2.6 | 9.8 |
IIV correlation matrix |
η
1 (CL/F) |
η
2 (V/F) |
η
3 (Ka) |
---|---|---|---|
η
1 (CL/F) | 1.000 | 0.647 | 0.224 |
η
2 (V/F) | 0.647 | 1.000 | −0.296 |
η
3 (K
a) | 0.224 | −0.296 | 1.000 |
3.2 Levetiracetam Population PK/PD Model for Adults and Pediatric Patients ≥4 Years
Parameter | Estimate (95% CI) | SE (%CV) | IIV (%) | Shrinkage responders (%) | Shrinkage placebo (%) |
---|---|---|---|---|---|
S
0 adults (day−1) | 0.337 (0.317–0.360) | 3.0 | 86.9 | 15.0 | 7.4 |
ES50 (seizures) | 2.75 (2.49–3.01) | 4.8 | |||
Smax (% increase) | 260.2 (238.1–283.7) | 2.5 | 119.8 | 66.2 | 64.2 |
Placebo (% change) | −14.8 (−18.7 to −10.7) | 15.1 | 40.7 | 43.2 | 29.7 |
E
max (% change) | −95.6 (−99.7 to −29.0) | 45.4 | 80.0 | 32.5 | 100.0 |
EC50 (mg/L) | 31.4 (6.34–156) | 23.7 | |||
Overdispersion | 0.107 (0.0907–0.125) | 3.6 | 291.0 | 63.7 | 63.9 |
Box–Cox parameter on S0
| 0.442 (0.367–0.517) | 8.7 | |||
Mixture fraction (fraction of subjects in the mixture-model responder population) | 0.335 (0.252–0.418) | 12.7 | |||
S0 (% change) pediatric subjects | 52.2 (31.2–76.6) | 18.0 |